| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb8f3eba86915d967beefc175437273a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caec9d278d03f50b618576bf65eb5506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab99ed601ef6bc23e51ab2ec1b30bb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c1bc6e8f9016c5fc16be810a5e361a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbb63f659143a648d5b14fb25bf6feb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e082fbc4283f9dbc473ed2584a0857f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a24ca8053b620752940cff9d03d61f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a25c1741b722351b79ede5a60120893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd2ac5d3f9d2d1b46ee5afbf1251746c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c08fd2e2733f114dfa4f90a8aac6dcf |
| publicationDate |
2014-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014144451-A2 |
| titleOfInvention |
Biomarkers for response to rapamycin analogs |
| abstract |
The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of- function of mTOR in therapeutic responsiveness to rapamycin analogs. Accordingly, in non-limiting embodiments, the present invention provides for assay methods and kits for determining the presence of loss of function mutations in TSC1 and/or TSC2 and/or gain-of- function of mTOR, and methods of using such determinations in selecting a therapeutic regimen for a cancer patient and in methods of treating cancer patients. In particular non-limiting embodiments, a plurality of tumor sites are evaluated and the composite effect of the genetic background on mTOR function is assessed. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |